Get the Stockscreener App
49.86
2.41%
-1.23
Pre-market:
49.88
0.02
+0.04%
Cytokinetics Inc stock is traded at $49.86, with a volume of 1.03M.
It is down -2.41% in the last 24 hours and down -9.30% over the past month.
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$51.09
Open:
$50.77
24h Volume:
1.03M
Relative Volume:
0.90
Market Cap:
$5.87B
Revenue:
$3.13M
Net Income/Loss:
$-545.28M
P/E Ratio:
-9.0326
EPS:
-5.52
Net Cash Flow:
$-401.27M
1W Performance:
-10.90%
1M Performance:
-9.30%
6M Performance:
-17.72%
1Y Performance:
+54.32%
1-Day Range:
$49.65
$50.95
1-Week Range:
$49.64
$56.31
52-Week Range:
$30.68
$110.25
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CYTK | 49.86 | 5.87B | 3.13M | -545.28M | -401.27M | -5.52 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Needham & Company LLC Reaffirms "Buy" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan - Yahoo Finance
Cytokinetics and Bayer ink deal for aficamten in Japan - The Pharma Letter
Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates - MSN
Bayer acquires rights to Cytokinetics' heart drug in Japan - MSN
Royce & Associates LP Has $1.28 Million Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics CEO Robert Blum sells shares for $252,750 - Investing.com
Cytokinetics CEO Robert Blum sells shares for $252,750 By Investing.com - Investing.com UK
Bayer (BAYRY) and Cytokinetics (CYTK) Collaborate on Japanese HC - GuruFocus.com
Cytokinetics, Bayer in Japan Licensing Pact for Aficamten - MarketWatch
Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer - Yahoo Finance
First Turn Management LLC Decreases Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan - Yahoo Finance UK
Bayer: exclusive licensing agreement with Cytokinetics in Japan - Marketscreener.com
Bayer secures rights to heart drug in multi-million deal - Marketscreener.com
Cytokinetics Lands €50M Bayer Deal for HCM Drug Aficamten in Japan, €580M+ Potential | CYTK Stock News - StockTitan
H.C. Wainwright keeps Buy rating on Cytokinetics shares, citing promising data on aficamten and omecamtiv - Investing.com Canada
Cytokinetics' (CYTK) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024 - The Manila Times
Principal Financial Group Inc. Sells 120,497 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024 - Marketscreener.com
Significant Portfolio Addition: T. Rowe Price Investment Managem - GuruFocus.com
Insider Sale at Cytokinetics Inc (CYTK): EVP Research & Developm - GuruFocus.com
Cytokinetics: On The Cusp Of Commercialization (NASDAQ:CYTK) - Seeking Alpha
Cytokinetics EVP sells $370,880 in stock By Investing.com - Investing.com Nigeria
Cytokinetics EVP sells $370,880 in stock - Investing.com
Cytokinetics' SWOT analysis: cardiac drug maker's stock poised for growth - Investing.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives $83.67 Average Price Target from Brokerages - MarketBeat
FMR LLC Bolsters Stake in Cytokinetics Inc - GuruFocus.com
Cytokinetics to Present at Jefferies London Healthcare Conference 2024 | CYTK Stock News - StockTitan
Lisanti Capital Growth LLC Sells 26,800 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference - Yahoo Finance
Cytokinetics Launches Phase 1 Trial for Novel Muscle Function Drug CK-089 | CYTK Stock News - StockTitan
HC Wainwright Forecasts Reduced Earnings for Cytokinetics - MarketBeat
Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4015089 - Marketscreener.com
Van ECK Associates Corp Has $3.80 Million Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics started at outperform by RBC, valuation cited - MSN
Eyeing drug launch in 2025, Cytokinetics rolls out HCM awareness campaign - MM+M Online
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Cytokinetics (NASDAQ:CYTK) Now Covered by Analysts at Royal Bank of Canada - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2024 Earnings Call Transcript - Insider Monkey
Cytokinetics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Cytokinetics: Q3 Earnings Snapshot - AOL
Cytokinetics director resigns, board reduced to eight By Investing.com - Investing.com UK
Cytokinetics (NASDAQ:CYTK) Posts Earnings Results, Misses Estimates By $0.09 EPS - MarketBeat
Cytokinetics Inc (CYTK) Q3 2024 Earnings Call Highlights: Strate - GuruFocus.com
Cytokinetics Inc (CYTK) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
Cytokinetics Inc earnings missed by $0.13, revenue fell short of estimates - Investing.com Canada
Cytokinetics Reports Third Quarter 2024 Financial Results - The Manila Times
International Assets Investment Management LLC Takes Position in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific Sessions 2024 - The Manila Times
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):